Anxo Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Anxo Pharmaceutical has a total shareholder equity of NT$842.1M and total debt of NT$840.3M, which brings its debt-to-equity ratio to 99.8%. Its total assets and total liabilities are NT$1.9B and NT$1.1B respectively. Anxo Pharmaceutical's EBIT is NT$67.1M making its interest coverage ratio 4.4. It has cash and short-term investments of NT$197.2M.
Key information
99.8%
Debt to equity ratio
NT$840.30m
Debt
| Interest coverage ratio | 4.4x |
| Cash | NT$197.21m |
| Equity | NT$842.10m |
| Total liabilities | NT$1.10b |
| Total assets | NT$1.94b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: 6677's short term assets (NT$735.0M) exceed its short term liabilities (NT$541.9M).
Long Term Liabilities: 6677's short term assets (NT$735.0M) exceed its long term liabilities (NT$554.7M).
Debt to Equity History and Analysis
Debt Level: 6677's net debt to equity ratio (76.4%) is considered high.
Reducing Debt: 6677's debt to equity ratio has reduced from 128.7% to 99.8% over the past 5 years.
Debt Coverage: 6677's debt is not well covered by operating cash flow (6.2%).
Interest Coverage: 6677's interest payments on its debt are well covered by EBIT (4.4x coverage).